Comparison_NN of_IN Serological_NP Detection_NP Methods_NP for_IN Diagnosis_NN of_IN Ehrlichia_NP canis_NNS Infections_NNS in_IN Dogs_NNS We_PP determined_VBD the_DT value_NN of_IN four_CD serological_JJ assays_NNS for_IN the_DT diagnosis_NN of_IN canine_JJ monocytic_JJ ehrlichiosis_NN by_IN comparing_VBG them_PP to_TO the_DT indirect_JJ fluorescent-antibody_NN assay_NN "_'' gold_NN standard_NN ._SENT "_'' The_DT specificity_NN of_IN Dip-S-Ticks_NN was_VBD significantly_RB lower_JJR than_IN that_DT of_IN all_DT of_IN the_DT other_JJ tests_NNS evaluated_VBD ._SENT The_DT sensitivity_NN of_IN Dip-S-Ticks_NN was_VBD significantly_RB higher_JJR than_IN that_DT of_IN Snap3Dx_NP or_CC the_DT Snap_NP Canine_NP Combo_NP ._SENT The_DT sensitivity_NN of_IN the_DT rMAP2_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) was_VBD significantly_RB higher_JJR than_IN that_DT of_IN the_DT Snap_NP Canine_NP Combo_NP ._SENT The_DT accuracy_NN levels_NNS of_IN the_DT rMAP2_JJ ELISA_NP ,_, Snap3Dx_NP ,_, Dip-S-Ticks_NP ,_, and_CC Snap_NP Canine_NP Combo_NP were_VBD 97.0_CD ,_, 89.8_CD ,_, 85.1_CD ,_, and_CC 82.9_CD %_NN ,_, respectively_RB ._SENT Canine_JJ monocytic_JJ ehrlichiosis_NN ,_, caused_VBN by_IN tick-transmitted_JJ Ehrlichia_NP canis_NNS ,_, has_VBZ been_VBN reported_VBN in_IN the_DT United_NP States_NPS and_CC throughout_IN most_JJS of_IN the_DT world_NN ,_, causing_VBG extensive_JJ morbidity_NN and_CC mortality_NN ._SENT Clinical_JJ and_CC hematologic_JJ abnormalities_NNS are_VBP often_RB nonspecific_JJ during_IN E._NP canis_NP infections_NNS ,_, and_CC coinfections_NNS with_IN other_JJ tick-transmitted_NN agents_NNS such_JJ as_IN E._NP chaffeensis_NN may_MD be_VB common_JJ ;_: thus_RB ,_, a_DT definitive_JJ diagnosis_NN may_MD be_VB difficult_JJ to_TO make_VB ._SENT The_DT indirect_JJ fluorescent-antibody_NN assay_NN (_( IFA_NP )_) is_VBZ the_DT method_NN most_RBS widely_RB used_VBN to_TO diagnose_VB E._NP canis_NNS infection_NN and_CC is_VBZ considered_VBN the_DT "_`` gold_JJ standard_NN "_'' ._SENT However_RB ,_, it_PP can_MD only_RB be_VB performed_VBN in_IN specialized_JJ laboratories_NNS ,_, reading_VBG of_IN results_NNS is_VBZ subjective_JJ ,_, and_CC it_PP does_VBZ not_RB differentiate_VB consistently_RB between_IN E._NP canis_NP and_CC E._NP chaffeensis_NN infections_NNS ._SENT There_EX is_VBZ a_DT tremendous_JJ need_NN for_IN other_JJ serological_JJ assays_NNS for_IN the_DT diagnosis_NN of_IN E._NP canis_NNS infection_NN in_IN dogs_NNS ._SENT A_DT variety_NN of_IN serodiagnostic_JJ tests_NNS are_VBP commercially_RB available_JJ ,_, but_CC the_DT diagnostic_JJ value_NN of_IN many_JJ of_IN these_DT tests_NNS remains_VBZ unevaluated_JJ ._SENT The_DT objective_NN of_IN the_DT present_JJ study_NN was_VBD to_TO determine_VB the_DT value_NN of_IN four_CD serological_JJ assays_NNS for_IN the_DT diagnosis_NN of_IN canine_JJ monocytic_JJ ehrlichiosis_NN by_IN comparing_VBG them_PP to_TO the_DT IFA_NP gold_NN standard_NN ._SENT A_DT total_NN of_IN 97_CD canine_JJ serum_NN samples_NNS was_VBD obtained_VBN from_IN the_DT College_NP of_IN Veterinary_NP Medicine_NP ,_, University_NP of_IN Florida_NP ,_, Gainesville_NP ,_, or_CC the_DT College_NP of_IN Veterinary_NP Medicine_NP ,_, North_NP Carolina_NP State_NP University_NP ,_, Raleigh_NP ._SENT Eighteen_CD IFA-positive_JJ serum_NN samples_NNS from_IN five_CD dogs_NNS experimentally_RB infected_VBN with_IN E._NP canis_NNS during_IN previous_JJ studies_NNS were_VBD used_VBN ._SENT Thirty-five_JJ serum_NN samples_NNS were_VBD from_IN naturally_RB infected_JJ dogs_NNS that_WDT had_VBD clinical_JJ signs_NNS consistent_JJ with_IN canine_JJ ehrlichiosis_NN and_CC positive_JJ IFA_NP titers_NNS (_( >=1:40_NN )_) ._SENT Forty-four_NP IFA-negative_NP serum_NN samples_NNS were_VBD obtained_VBN from_IN clinically_RB healthy_JJ dogs_NNS during_IN well-patient_JJ visits_NNS or_CC preinfection_NN from_IN experimentally_RB infected_JJ dogs_NNS ._SENT All_DT serum_NN samples_NNS were_VBD tested_VBN blindly_RB in_IN the_DT following_VBG serological_JJ assays_NNS ._SENT All_DT serum_NN samples_NNS ,_, diluted_VBD 1/300_CD ,_, were_VBD tested_VBN with_IN the_DT rMAP2_JJ indirect_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) as_RB described_VBD previously_RB ._SENT The_DT samples_NNS were_VBD tested_VBN for_IN canine_JJ ehrlichiosis_NN with_IN the_DT Snap_NP Canine_NP Combo_NP test_NN kit_NN ,_, the_DT new_JJ Snap3Dx_NP assay_NN (_( IDEXX_NP Laboratories_NP ,_, Inc._NP )_) ,_, and_CC the_DT InDx_NP canine_JJ multitest_NN Dip-S-Ticks_NN assay_NN (_( PanBio_NP InDx_NP ,_, Inc._NP ,_, Baltimore_NP ,_, Md._NP )_) in_IN accordance_NN with_IN the_DT manufacturers_NNS '_POS recommendations_NNS ._SENT The_DT data_NNS were_VBD analyzed_VBN by_IN using_VBG SigmaStat_NP ,_, version_NN 2.03_CD ,_, for_IN Windows_NP (_( SPSS_NP Inc._NP )_) and_CC calculated_VBN as_IN described_VBN by_IN Courtney_NP and_CC Cornell_NP ._SENT As_IN observed_VBN in_IN Table_NP ,_, a_DT sensitivity_NN of_IN 96.2_CD %_NN was_VBD obtained_VBN with_IN the_DT rMAP2_JJ ELISA_NP ._SENT Its_PP$ specificity_NN was_VBD 97.7_CD %_NN ,_, as_RB one_CD false-positive_NN reaction_NN was_VBD detected_VBN ._SENT The_DT latter_JJ serum_NN sample_NN was_VBD positive_JJ with_IN the_DT Dip-S-Tick_NP assay_NN but_CC negative_JJ by_IN both_DT Snap_NP tests_NNS ._SENT The_DT sensitivity_NN of_IN the_DT rMAP2_JJ ELISA_NP was_VBD significantly_RB higher_JJR than_IN that_DT of_IN the_DT Snap_NP Canine_NP Combo_NP (_( P_NN =_SYM 0.001_CD )_) ._SENT Also_RB ,_, the_DT sensitivity_NN of_IN the_DT Dip-S-Ticks_NN was_VBD significantly_RB higher_JJR than_IN that_DT of_IN the_DT Snap3Dx_NP (_( P_NN =_SYM 0.003_CD )_) or_CC the_DT Snap_NP Canine_NP Combo_NP (_( P_NN <=_NN 0.001_CD )_) ._SENT The_DT specificity_NN of_IN the_DT Dip-S-Ticks_NN was_VBD significantly_RB lower_JJR than_IN that_DT of_IN all_DT of_IN the_DT other_JJ tests_NNS evaluated_VBN (_( P_NN <=_0.001). =5,000_NN were_VBD positive_JJ in_IN the_DT 1:5,000-to-1:10,000_JJ Dip-S-Ticks_NN window_NN ._SENT No_DT false_JJ positives_NNS were_VBD recorded_VBN for_IN the_DT second_JJ test_NN window_NN ._SENT Twenty-eight_JJ percent_NN of_IN the_DT serum_NN samples_NNS within_IN an_DT IFA_NP titer_NN range_NN of_IN 1:320_CD to_TO 1:2,560_CD were_VBD reactive_JJ in_IN the_DT 1:5,000-to-1:10,000_JJ Dip-S-Tick_NP window_NN ._SENT One_CD of_IN the_DT strengths_NNS of_IN this_DT study_NN was_VBD that_IN it_PP used_VBD duplicate_JJ sera_NN from_IN the_DT same_JJ dogs_NNS to_TO compare_VB different_JJ serodiagnostic_JJ tests_NNS ._SENT The_DT assays_NNS tested_VBN in_IN this_DT study_NN varied_VBN in_IN the_DT ability_NN to_TO detect_VB E._NP canis_NNS antibodies_NNS ._SENT The_DT Dip-S-Ticks_NN assay_NN was_VBD 100_CD %_NN sensitive_JJ in_IN detecting_VBG sera_NN from_IN infected_JJ dogs_NNS but_CC lacked_VBD specificity_NN ,_, as_IN a_DT high_JJ percentage_NN of_IN false_JJ positives_NNS was_VBD reported_VBN ._SENT This_DT may_MD be_VB due_JJ to_TO the_DT fact_NN that_IN whole_JJ cells_NNS from_IN E._NP canis_NP (_( Jake_NP strain_NN )_) were_VBD used_VBN as_IN antigens_NNS causing_VBG cross-reactivities_NNS and_CC thus_RB false-positive_JJ reactions_NNS ._SENT Semiquantitative_JJ results_NNS can_MD be_VB obtained_VBN with_IN the_DT Dip-S-Ticks_NN assay_NN ;_: however_RB ,_, the_DT Dip-S-Ticks_NN titers_NNS did_VBD not_RB always_RB correspond_VB to_TO the_DT reported_JJ IFA_NP titers_NNS ._SENT Reading_VBG of_IN the_DT assay_NN strips_NNS was_VBD difficult_JJ when_WRB recording_VBG borderline_JJ reactions_NNS and_CC may_MD have_VB led_VBN to_TO misleading_VBG interpretations_NNS and_CC to_TO the_DT high_JJ percentage_NN of_IN false_JJ positives_NNS recorded_VBD ._SENT Also_RB ,_, the_DT range_NN between_IN the_DT upper_JJ and_CC lower_JJR confidence_NN limits_NNS was_VBD wide_JJ because_IN of_IN the_DT limited_JJ number_NN of_IN samples_NNS available_JJ within_IN each_DT of_IN the_DT infected_JJ or_CC uninfected_JJ groups_NNS ._SENT Previously_RB ,_, we_PP demonstrated_VBD 97.2_CD %_NN overall_JJ agreement_NN between_IN the_DT IFA_NP and_CC the_DT rMAP2_JJ ELISA_NP for_IN E._NP canis_NP antibody_NN detection_NN ._SENT In_IN this_DT study_NN ,_, 96.2_CD %_NN sensitivity_NN and_CC 97.7_CD %_NN specificity_NN were_VBD obtained_VBN with_IN the_DT E._NP canis_NN rMAP2_NN ELISA_NP ._SENT The_DT rMAP2_JJ ELISA_NP has_VBZ the_DT advantage_NN of_IN being_VBG a_DT quantitative_JJ test_NN ._SENT Therefore_RB ,_, detection_NN of_IN recent_JJ exposure_NN and_CC active_JJ infection_NN can_MD be_VB done_VBN by_IN comparing_VBG paired_VBN titers_NNS ._SENT The_DT use_NN of_IN recombinant_JJ proteins_NNS ,_, such_JJ as_IN p30_NN and_CC p43_NN ,_, to_TO increase_VB the_DT quality_NN of_IN the_DT test_NN antigen_NN and_CC to_TO eliminate_VB test_NN subjectivity_NN in_IN Western_JJ immunoblot_NN and_CC dot_VBP blot_NN assays_NNS was_VBD demonstrated_VBN previously_RB ._SENT The_DT Snap_NP Canine_NP Combo_NP from_IN IDEXX_NP ,_, which_WDT uses_VBZ whole_JJ cells_NNS of_IN E._NP canis_NNS strain_VBP Oklahoma_NP as_IN the_DT antigen_NN ,_, is_VBZ being_VBG replaced_VBN on_IN the_DT market_NN by_IN the_DT new_JJ Snap3Dx_NP assay_NN ,_, which_WDT uses_VBZ recombinant_JJ analogs_NNS of_IN the_DT major_JJ outer_JJ membrane_NN proteins_NNS ,_, specifically_RB ,_, p30_NN and_CC p30-1_JJ ._SENT According_VBG to_TO our_PP$ study_NN ,_, the_DT sensitivity_NN and_CC specificity_NN of_IN the_DT Snap3Dx_NP assay_NN were_VBD 15_CD and_CC 2.3_CD %_NN higher_JJR ,_, respectively_RB ,_, when_WRB recombinant_JJ proteins_NNS were_VBD used_VBN as_IN antigens_NNS instead_RB of_IN E._NP canis_NP whole_JJ cells_NNS ._SENT However_RB ,_, these_DT differences_NNS were_VBD not_RB statistically_RB significant_JJ within_IN the_DT limited_JJ sample_NN size_NN ._SENT The_DT Snap3Dx_NP assay_NN combines_VBZ specificity_NN and_CC rapidity_NN and_CC can_MD be_VB used_VBN in_IN any_DT clinic_NN ._SENT The_DT rMAP2_JJ ELISA_NP ,_, even_RB though_IN it_PP is_VBZ more_JJR time_NN consuming_NN and_CC is_VBZ not_RB applicable_JJ to_TO all_DT laboratories_NNS ,_, provides_VBZ high_JJ sensitivity_NN ,_, high_JJ specificity_NN ,_, quantitative_JJ results_NNS ,_, and_CC the_DT convenience_NN of_IN the_DT ability_NN to_TO test_VB many_JJ samples_NNS in_IN a_DT short_JJ time_NN ._SENT Its_PP$ accuracy_NN ,_, which_WDT reflects_VBZ the_DT chance_NN of_IN correctly_RB identifying_VBG the_DT infection_NN status_NN of_IN an_DT animal_NN ,_, was_VBD the_DT highest_JJS among_IN the_DT assays_NNS tested_VBD ._SENT In_IN choosing_VBG a_DT serodiagnostic_JJ test_NN for_IN a_DT laboratory_NN ,_, one_PP should_MD take_VB into_IN consideration_NN many_JJ factors_NNS ,_, including_VBG the_DT cost_NN of_IN the_DT test_NN ,_, its_PP$ rapidity_NN ,_, its_PP$ convenience_NN of_IN use_NN ,_, the_DT sample_NN load_NN ,_, and_CC the_DT predictive_JJ value_NN of_IN a_DT positive_JJ or_CC negative_JJ result_NN ._SENT The_DT seroprevalence_NN of_IN E._NP canis_NNS infection_NN within_IN different_JJ canine_JJ populations_NNS may_MD vary_VB dramatically_RB ._SENT For_IN example_NN ,_, in_IN a_DT recent_JJ survey_NN of_IN sick_JJ dogs_NNS from_IN North_NP Carolina_NP and_CC Virginia_NP ,_, the_DT seroprevalence_NN of_IN E._NP canis_NNS was_VBD estimated_VBN to_TO be_VB 2.5_CD %_NN ._SENT On_IN the_DT basis_NN of_IN our_PP$ study_NN and_CC an_DT E._NP canis_NN prevalence_NN of_IN 2.5_CD %_NN ,_, the_DT calculated_JJ predictive_JJ values_NNS of_IN positive_JJ and_CC negative_JJ results_NNS were_VBD both_DT 100_CD %_NN for_IN the_DT Snap3Dx_NP test_NN ._SENT Therefore_RB ,_, if_IN the_DT prevalence_NN of_IN E._NP canis_NP infection_NN is_VBZ expected_VBN to_TO be_VB low_JJ in_IN the_DT population_NN tested_VBD ,_, the_DT Snap3Dx_NP test_NN would_MD be_VB an_DT excellent_JJ test_NN to_TO help_VB in_IN the_DT identification_NN of_IN such_JJ infections_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Predictive_JJ values_NNS of_IN positive_JJ (_( A_NP )_) and_CC negative_JJ (_( B_NP )_) rMAP2_NP ELISA_NP ,_, Dip-S-Ticks_NP ,_, Snap_NP Combo_NP ,_, and_CC Snap3DX_NP results_NNS at_IN prevalence_NN rates_NNS ranging_VBG from_IN 0_CD to_TO 100_CD %_NN with_IN IFA_NP as_IN the_DT reference_NN standard_NN test_NN ._SENT Predictive_JJ values_NNS of_IN positive_JJ (_( A_NP )_) and_CC negative_JJ (_( B_NP )_) rMAP2_NP ELISA_NP ,_, Dip-S-Ticks_NP ,_, Snap_NP Combo_NP ,_, and_CC Snap3DX_NP results_NNS at_IN prevalence_NN rates_NNS ranging_VBG from_IN 0_CD to_TO 100_CD %_NN with_IN IFA_NP as_IN the_DT reference_NN standard_NN test_NN ._SENT Alternatively_RB ,_, for_IN serodiagnosis_NN during_IN an_DT outbreak_NN or_CC when_WRB testing_NN dogs_NNS with_IN clinical_JJ and/or_CC laboratory_NN findings_NNS consistent_JJ with_IN canine_JJ ehrlichiosis_NN ,_, the_DT chances_NNS of_IN finding_VBG more_JJR E._NP canis_NNS infections_NNS are_VBP higher_JJR and_CC the_DT predictive_JJ values_NNS of_IN the_DT results_NNS obtained_VBN in_IN such_PDT an_DT environment_NN would_MD be_VB different_JJ ._SENT Kordick_NP and_CC colleagues_NNS reported_VBD an_DT E._NP canis_NN prevalence_NN of_IN 55.6_CD %_NN in_IN a_DT Walker_NP Hound_NP kennel_NN in_IN North_NP Carolina_NP during_IN an_DT outbreak_NN ._SENT In_IN this_DT case_NN ,_, the_DT rMAP2_JJ ELISA_NP would_MD be_VB a_DT good_JJ choice_NN as_IN its_PP$ predictive_JJ value_NN of_IN positive_JJ and_CC negative_JJ results_NNS would_MD be_VB 98.1_CD and_CC 95.4_CD %_NN ,_, respectively_RB ._SENT It_PP must_MD be_VB emphasized_VBN that_IN serodiagnostic_JJ assays_NNS do_VBP not_RB distinguish_VB between_IN current_JJ infection_NN and_CC prior_JJ exposure_NN ._SENT In_IN this_DT study_NN ,_, specificity_NN was_VBD determined_VBN in_IN relation_NN to_TO that_DT of_IN IFA_NP ,_, the_DT gold_JJ standard_NN ._SENT The_DT IFA_NP and_CC most_JJS of_IN the_DT rapid_JJ serodiagnostic_JJ tests_NNS do_VBP not_RB differentiate_VB among_IN E._NP canis_NP ,_, E._NP chaffeensis_NN ,_, and_CC E._NP ewingii_NP infections_NNS in_IN dogs_NNS ,_, as_IN these_DT species_NNS are_VBP closely_RB related_JJ and_CC have_VB some_DT cross-reacting_NN antigens_NNS ._SENT It_PP has_VBZ been_VBN observed_VBN that_IN the_DT clinical_JJ disease_NN ,_, prognosis_NN ,_, and_CC potential_JJ drug_NN efficacy_NN associated_VBN with_IN E._NP canis_NP or_CC E._NP chaffeensis_NN infection_NN may_MD differ_VB ._SENT Therefore_RB ,_, further_JJR development_NN of_IN tests_NNS for_IN canine_JJ monocytic_JJ ehrlichiosis_NN should_MD address_VB this_DT important_JJ problem_NN and_CC try_VB to_TO eliminate_VB cross-reactivities_NNS to_TO provide_VB a_DT more_RBR accurate_JJ diagnosis_NN ._SENT 